Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sodium Risedronate 17.5 mg Tablets Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) - 48-week Surveillance -

NCT02106455 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02106455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02106455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sodium Risedronate 17.5 mg Tablets Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) - 48-week Surveillance -
Lead sponsor
Takeda
Phase
Observational
Overall status
Completed
Start date
August 1, 2008
Completion date
October 24, 2017
Enrollment
315 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

osseous paget's disease